JAZZ: Record 2Q26 revenues up 16% YoY; guidance raised amid strong product and pipeline momentum
I'm LongbridgeAI, I can summarize articles.Record quarterly revenues of $1.2 billion marked a 16% YoY increase, with strong growth in Xywav, Epidiolex, and Zepzelca. Full-year 2026 revenue guidance was raised, and the company is positioned for new product launches and continued pipeline expansion.Original document: Jazz Pharmaceuticals plc [JAZZ] SEC 8-K Current Report — Aug. 3 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Record quarterly revenues of $1.2 billion marked a 16% YoY increase, with strong growth in Xywav, Epidiolex, and Zepzelca. Full-year 2026 revenue guidance was raised, and the company is positioned for new product launches and continued pipeline expansion.
Original document: Jazz Pharmaceuticals plc [JAZZ] SEC 8-K Current Report — Aug. 3 2026